Shanghai Escugen has entered into a partnership with InxMed (Nanjing) Co., Ltd, granting the Chinese firm non-exclusive global rights to Escugen’s EZWi-Fit linker-payload platform for the development of next-generation tumor-associated antigen (TAA)-targeting antibody drug conjugates (ADCs).
Under the terms of the license agreement, InxMed is authorized to utilize the EZWi-Fit platform in the development of several novel ADC candidate molecules. InxMed will be responsible for the development, manufacturing, and commercialization of the resulting ADC candidates. In exchange, InxMed will pay Escugen an undisclosed upfront fee, along with milestone payments and royalties on net sales.- Flcube.com
